CDChristopher J. DiMaio

Christopher J. DiMaio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher J. DiMaio has a total of 428 co-authors. Here are the top co-authors by number of shared publications:

  • Susana Gonzalez

    Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    6 shared publications
  • Andrew Y. Wang

    Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia

    4 shared publications
  • Brian P. Riff

    The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    4 shared publications
  • Rabindra R. Watson

    Division of Digestive Diseases, University of California at Los Angeles School of Medicine, Los Angeles, California, United States

    4 shared publications
  • Satish Nagula

    Center for Advanced Colonoscopy and Therapeutic Endoscopy at Sinai (CACTES), Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States

    4 shared publications
  • Sunil Amin

    Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    4 shared publications

Latest Publications

  • Transoral Incisionless Fundoplication in Patients With Barrett's Esophagus

    by Nicholas A. Hoerter, Michael S. Smith, Rebekah E. Dixon, Zachary Spiera, Monica Saumoy, Prashant Kedia, David P. Lee, Nikhil A. Kumta, Satish Nagula, Christopher J. DiMaio

  • Tandem peroral endoscopic myotomy (POEM) and transoral incisionless fundoplication: a strategy to reduce reflux after POEM

    by Nicholas A. Hoerter, Rebekah E. Dixon, Christopher J. DiMaio, Satish Nagula, David Greenwald, Nikhil A. Kumta

    Peroral endoscopic myotomy (POEM) is an effective treatment for achalasia, comparable to laparoscopic Heller myotomy (LHM) [1]. Gastroesophageal reflux disease (GERD) is a common adverse event, and POEM vs. LHM has higher abnormal acid exposure (39 % vs. 16.8 %) and esophagitis (29.4 % vs. 7.6 %) [2] [3]. Transoral incisionless fundoplication (TIF) is an endoscopic intervention for GERD that reduces acid exposure [4] [5]. A 41-year-old man with manometry-confirmed type II achalasia presented with dysphagia to solids and liquids and weight loss. His Eckardt score was 11 out of 12 (severe symptoms). The plan was to perform POEM followed by TIF in a single session to reduce post-POEM reflux ([Video 1]). Video 1 Tandem peroral endoscopic myotomy and transoral incisionless fundoplication. Mucosotomy closure with endoscopic suturing. The endoscope was fitted with a clear, tapered cap. A submucosal injection of saline plus methylene blue followed by mucosotomy were performed 10 cm proximally to the gastroesophageal junction (GEJ) ([Fig. 1]). The submucosal space was entered and the tunnel extended 2 cm beyond the GEJ ([Fig. 2]). A full-thickness myotomy was extended 2 cm beyond the lower esophageal sphincter ([Fig. 3]). The fundoplication device was inserted and the GEJ was viewed in retroflexion. Tissue was pulled into the device using a tissue helix and suction. Device manipulation and deployment of 28 H-shaped full-thickness fasteners were used to augment the GEJ flap valve to create a 270-degree wrap 2 cm in length ([Fig. 4]). The mucosotomy was closed by endoscopic suturing ([Fig. 5]). The patient was discharged the day after tandem POEM-TIF. He regained weight and his Eckhardt score improved from 11 to 3. He reported no reflux or need for proton pump inhibitors. Follow-up esophagogastroduodenoscopy 9 months later showed no esophagitis. Tandem POEM-TIF is a strategy for prevention of reflux after POEM, especially in young patients. Further study is needed to determine long-term safety and efficacy. Endoscopy_UCTN_Code_CPL_1AH_2AH Publication Date: 09 August 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Management of a necrosed bile duct by combination of a fully covered metal biliary stent and endoscopic ultrasound-guided gastrojejunostomy

    by Christopher J. DiMaio, Antonio R. Cheesman, Satish Nagula, Nikhil A. Kumta

    Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is an emerging procedure in the management of gastric outlet obstruction [1] [2] [3] [4] [5]. One potential application of EUS-GJ is to divert luminal contents away from a luminal defect in order to minimize infection and/or facilitate healing. The patient is a 71-year-old man with a history of pancreatic adenocarcinoma and uncovered metal biliary stent placement 16 months ago who was admitted with cholangitis and bacteremia (E. coli and Klebsiella) secondary to an occluded biliary stent. Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated tumor infiltration of the medial duodenal wall with an associated necrotic debris-filled cavity ([Video 1]). The lateral wall of the indwelling metal stent was clearly visible in the cavity, consistent with necrosis of the bile duct ([Fig. 1]). Video 1 Management of cholangitis from a necrotic bile duct with combined fully covered metal biliary stent and endoscopic ultrasound-guided gastrojejunostomy. Cholangiogram demonstrated extravasation of contrast through the stent side holes into a contained cavity ([Fig. 2]). To prevent further contamination of the biliary tree, a 10-mm × 60-mm fully covered metal biliary stent (Wallflex; Boston Scientific, Marlborough, Massachusetts, USA) was placed within the uncovered stent ([Fig. 3]). Repeat cholangiogram confirmed no further extravasation. To minimize the risk of further soiling of the necrotic cavity and bile duct, EUS-GJ was pursued with the goal of diverting luminal contents away from this area. Approximately 250 cc of a dilute methylene blue/saline/contrast solution was infused into the proximal jejunum. A loop of jejunum adjacent to the gastric wall was identified and a 15-mm × 10-mm electrocautery-enhanced lumen-apposing metal stent (LAMS) (Hot Axios; Boston Scientific) was placed ([Fig. 4]). The patient tolerated the procedure well and was started on a clear liquid diet that night. He was discharged home 2 days later. At 1 month follow-up, the patient was eating a full diet and was otherwise doing well. This case demonstrates a novel use of endoscopic ultrasound-guided gastrojejunostomy to manage a gastrointestinal luminal defect. Other potential applications may include management of gastroduodenal fistulas, perforations, and post-operative leaks. Endoscopy_UCTN_Code_CPL_1AK_2AD Publication Date: 20 August 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York

  • Open Access

    Digestive Manifestations in Patients Hospitalized with COVID-19

    by B. Joseph Elmunzer, Rebecca L. Spitzer, Lydia D. Foster, Ambreen A. Merchant, Eric F. Howard, Vaishali A. Patel, Mary K. West, Emad Qayed, Rosemary Nustas, Ali Zakaria, et al.

    Background: The prevalence and significance of digestive manifestations in COVID-19 remain uncertain. Methods: Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. Results: A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death. Conclusions: Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course


  • Open Access

    Primary EUS-guided biliary drainage versus ERCP drainage for the management of malignant biliary obstruction: A systematic review and meta-analysis

    by ChristopherJ DiMaio, Gaurav Kakked, Habeeb Salameh, AntonioR Cheesman, NikhilA Kumta, Satish Nagula

    EUS-guided biliary drainage (EUS-BD) has been used as a salvage modality for relief of malignant biliary obstruction (MBO) after a failed ERCP. Multiple recent randomized controlled trials (RCTs) and observational studies have been published to assess the suitability of EUS-BD as a first-line modality for achieving palliative BD. We aimed to perform a systematic review and meta-analysis comparing primary EUS-BD versus ERCP for MBO. We searched PubMed, Medline, and Embase up to January 1, 2019, to identify RCTs and observational studies evaluating the efficacy and safety of primary EUS-BD (without a prior attempted ERCP) versus ERCP. Quality of RCTs and observational studies was assessed using Jadad and Newcastle-Ottawa scores, respectively. The outcomes of interest were technical success, clinical success, odds of requiring a repeat intervention, and procedure-related adverse events. Odds ratios (ORs) and standard mean difference were calculated for categorical and continuous variables, respectively. Meta-analysis was performed using the random effects model in RevMan 5.3 (the Cochrane Collaboration, the Nordic Cochrane Centre, Copenhagen, Denmark). Five studies (three RCTs and two observational studies) with 361 patients were included. Both procedures achieved comparable technical success (OR: 1.20 [0.44-3.24], I2 = 0%) and clinical success (OR: 1.44, confidence interval [CI]: 0.63-3.29, I2 = 0%). The overall adverse outcomes (OR: 1.59 [0.89-2.84]) did not differ between the two groups. In the ERCP group, 9.5% of patients developed procedure-related pancreatitis versus zero in the EUS group (risk difference = 0.08%, P = 0.02). There was no statistically significant difference in nonpancreatitis-related adverse events. The odds of requiring reintervention for BD (1.68 [0.76-3.73], I2 = 42%) did not differ significantly. The ERCP group had significantly higher odds of requiring reintervention due to tumor overgrowth (5.35 [1.64-17.50], I2 = 0%). EUS-BD has comparable technical and clinical success to ERCP and can potentially be used as a first-line palliative modality for MBO where expertise is available. ERCP-related pancreatitis which can cause significant morbidity can be completely avoided with EUS.


  • ERCP in Chronic Pancreatitis

    by Antonio R. Cheesman, Christopher J. DiMaio

  • Correction: Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study

    by Juliana Yang, Yen-I Chen, Shai Friedland, Ian Holmes, Christopher Paiji, Ryan Law, Amy Hosmer, Tyler Stevens, Franco Matheus, Rishi Pawa, et al.

    Yang J, Chen YI, Friedland S et al. Lumen-apposing stents versus plastic stents in the management of pancreatic pseudocysts: a large, comparative, international, multicenter study Endoscopy, DOI 10.1055/a-0759-1353 In the above-mentioned article, the name of the author Srinivas Gaddam has been corrected. This was corrected in the online version on February 14, 2019


  • Management of complications of acute pancreatitis

    by Christopher J. DiMaio

    Acute pancreatitis can result in a number of localized complications such as pancreatic pseudocysts, walled-off pancreatic necrosis (WON), and disconnected pancreatic duct syndrome (DPDS). The management of these conditions has evolved over the past three decades such that minimally invasive endoscopic drainage and debridement methods are now the favored, first-line approach. This article will review the latest developments and controversies regarding the endoscopic management of these conditions. For patients with pancreatic pseudocysts, it remains to be clear what the role of routine ERCP is in this population. For WON, it is clear that when expertise is available, a minimally invasive approach may be the most suitable option. There is a growing literature raising concern about LAMS-associated bleeding in this group, however. Alterations in LAMS placement and stent dwell time may reduce this risk. Lastly, recognition of the DPDS is an important factor that needs to be recognized whenever present, as these patients will require a long-term management strategy and may require multimodality intervention. Despite the development of new endoscopic techniques and dedicated devices for managing pancreatic fluid collections and disconnected pancreatic duct syndrome, a number of issues remain unresolved in terms of best practice methods.